S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The only accurate crypto trading system I know … (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
How Biden has already won 2024 (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Your Money is Not Safe (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The only accurate crypto trading system I know … (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
How Biden has already won 2024 (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Your Money is Not Safe (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The only accurate crypto trading system I know … (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
How Biden has already won 2024 (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Your Money is Not Safe (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The only accurate crypto trading system I know … (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
How Biden has already won 2024 (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Your Money is Not Safe (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Free Trial
LON:ROQ

Roquefort Therapeutics (ROQ) Share Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)
Free ROQ Stock Alerts
GBX 4.75
+0.20 (+4.40%)
(As of 04/18/2024 09:23 PM ET)
Compare
Today's Range
4.50
▼
4.75
50-Day Range
4
▼
9.25
52-Week Range
3.90
▼
9.50
Volume
332,328 shs
Average Volume
319,000 shs
Market Capitalization
£6.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsHeadlinesInsider Trades
ROQ stock logo

About Roquefort Therapeutics Stock (LON:ROQ)

Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.

ROQ Stock Price History

ROQ Stock News Headlines

April 19, 2024 | americanbankingnews.com
Roquefort Therapeutics (LON:ROQ) Trading Down 1.1%
April 5, 2024 | msn.com
UK Stocks: Here’s Why Roquefort (ROQ) Share Price is Crashing
April 19, 2024 | InvestorPlace (Ad)
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
March 11, 2024 | lse.co.uk
Roquefort celebrates "significant milestones" in cancer research
March 11, 2024 | uk.investing.com
Roquefort Therapeutics reveals progress with liver and colorectal cancer programmes
December 21, 2023 | seekingalpha.com
NBSE NeuBase Therapeutics, Inc.
November 6, 2023 | lse.co.uk
Roquefort Therapeutics MK cell programme shows positive results
September 27, 2023 | proactiveinvestors.com
Roquefort Therapeutics preparing targets for clinic as eyes commercial deals
April 19, 2024 | InvestorPlace (Ad)
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
September 27, 2023 | proactiveinvestors.com
Roquefort Therapeutics preparing targets for clinic as it eyes commercial deals
August 17, 2023 | finance.yahoo.com
Roquefort Therapeutics seeks to lock in future value with anti-cancer therapeutic patents
August 9, 2023 | finance.yahoo.com
Roquefort Therapeutics making headway with siRNA
June 29, 2023 | proactiveinvestors.com
Roquefort Therapeutics highlights significant progress at AGM
June 22, 2023 | proactiveinvestors.com
Roquefort Therapeutics hails significant pre-clinical results
June 22, 2023 | marketwatch.com
Roquefort Therapeutics Makes Progress on Cancer Treatment
June 16, 2023 | finance.yahoo.com
Roquefort Therapeutics returns to the market with new study data
June 13, 2023 | marketwatch.com
Roquefort Therapeutics' Anti-Cancer MRNA Study Showed Positive Results
June 7, 2023 | marketwatch.com
Roquefort Therapeutics Resumes Trading After Publishing 2022 Results
June 5, 2023 | proactiveinvestors.com
Roquefort Therapeutics eyes second half progress
March 13, 2023 | proactiveinvestors.com
Roquefort Therapeutics has no exposure to SVB
March 8, 2023 | proactiveinvestors.com
Roquefort Therapeutics says new mRNA platform "fits very well"
March 8, 2023 | proactiveinvestors.com
Roquefort develops a fifth programme using a technology pioneered by Moderna and BioNTech
March 6, 2023 | proactiveinvestors.com
Roquefort Therapeutics establishes scientific advisory board
February 22, 2023 | lse.co.uk
Roquefort Thera Regulatory News
February 21, 2023 | barrons.com
Roquefort Therapeutics PLC
February 20, 2023 | proactiveinvestors.com
Roquefort Therapeutics inks Randox diagnostic deal
February 20, 2023 | proactiveinvestors.com
Roquefort Therapeutics inks first strategic licensing deal with diagnostics firm Randox
See More Headlines
Receive ROQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:ROQ
CUSIP
N/A
CIK
N/A
Web
www.roquefortinvest.com
Phone
44 20 3290 9339
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-1,640,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-33.20%
Return on Assets
-19.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.66
Quick Ratio
3.07

Sales & Book Value

Annual Sales
£637.00
Price / Sales
9,123.63
Cash Flow
GBX 3.01 per share
Price / Cash Flow
1.49
Book Value
GBX 5 per share
Price / Book
0.90

Miscellaneous

Outstanding Shares
129,150,000
Free Float
N/A
Market Cap
£5.81 million
Optionable
Not Optionable
Beta
-0.03
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Stephen Paul West B.Com (Age 52)
    CA, Executive Chairman
    Comp: $118.31k
  • Mr. Trevor Ajanthan Reginald (Age 52)
    CEO & Executive Director
    Comp: $284.1k
  • Prof. Martin J. Evans FRS (Age 83)
    Group Chief Scientific Officer & Executive Director
    Comp: $101.22k
  • Dr. Emma Morris
    Head of Pre-Clinical Research

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ROQ Stock Analysis - Frequently Asked Questions

How have ROQ shares performed in 2024?

Roquefort Therapeutics' stock was trading at GBX 7.25 at the start of the year. Since then, ROQ shares have decreased by 37.9% and is now trading at GBX 4.50.
View the best growth stocks for 2024 here.

How do I buy shares of Roquefort Therapeutics?

Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:ROQ) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research